Literature Survey: The Effect of Glidants on the Tabletting Behavior

Literature Survey: The Effect of Glidants on the Tabletting Behavior of Common Pharmaceutical Excipients

Introduction

In pharmaceutical tablet formulation, the role of excipients is crucial in ensuring the efficacy, stability, and manufacturability of the final product. Among these excipients, glidants play a pivotal role in enhancing the flow properties of powder blends, which is critical for the uniformity and quality of tablets. This literature survey explores the impact of glidants on the tabletting behavior of common pharmaceutical excipients.

Overview of Glidants

Glidants are substances added to powder blends to improve their flowability by reducing inter-particle friction. Common glidants used in the pharmaceutical industry include colloidal silicon dioxide, talc, and magnesium stearate. These agents are typically added in small quantities but can significantly affect the mechanical properties of the tablet, such as hardness, friability, and disintegration time.

Influence on Flowability

The primary function of glidants is to enhance the flowability of powder blends. Flowability is critical for ensuring uniform die filling and preventing weight variation in tablets. Flow properties are often measured using parameters like Hausner's ratio and Carr's index. Studies have shown that the addition of colloidal silicon dioxide at concentrations as low as 0.5% can significantly reduce the Hausner's ratio and Carr's index, indicating improved flow properties . This improvement is attributed to the glidant's ability to coat the particles, reducing inter-particle cohesion and adhesion .

Impact on Compaction and Tablet Hardness

The compaction behavior of excipients is influenced by their ability to deform under pressure, which is critical for achieving tablets with desired mechanical properties. Glidants can modify this behavior by acting as lubricants during the tabletting process. Research indicates that talc and colloidal silicon dioxide can affect the plastic deformation of excipients like microcrystalline cellulose (MCC) and lactose . While glidants generally improve flowability, they can also interfere with particle bonding, potentially leading to a decrease in tablet hardness. A study demonstrated that tablets containing higher concentrations of talc exhibited reduced hardness and increased friability, which could affect the mechanical stability of the tablet .

Effects on Disintegration and Dissolution

The presence of glidants can also influence the disintegration and dissolution profiles of tablets, which are critical for ensuring the bioavailability of the active pharmaceutical ingredient (API). Glidants like magnesium stearate, known for its hydrophobic nature, can create a barrier around particles, delaying the tablet's disintegration and dissolution . In contrast, colloidal silicon dioxide, being less hydrophobic, has a minimal impact on the disintegration time and can sometimes enhance the dissolution rate by improving the wettability of the tablet surface .

Specific Excipient-Glidant Interactions

1. Microcrystalline Cellulose (MCC): MCC is a widely used diluent and binder in tablet formulations. The addition of glidants like colloidal silicon dioxide to MCC has been shown to improve its flow properties without significantly compromising tablet hardness and disintegration time . However, excessive amounts of talc can lead to weaker tablets. A study by Bolhuis and Armstrong (2006) indicated that while MCC's compressibility is high, its flow properties benefit significantly from the addition of glidants, ensuring consistent tablet quality .
2. Lactose: Lactose is another common excipient that benefits from glidant addition. Studies have found that the inclusion of colloidal silicon dioxide can enhance the flowability and compaction of lactose-based formulations, resulting in tablets with uniform weight and adequate mechanical strength . However, lactose’s brittleness can be exacerbated by overuse of glidants, leading to potential friability issues.
3. Starch: Starch, used as a disintegrant and binder, can exhibit improved flow properties when combined with glidants. However, the interaction between starch and glidants like magnesium stearate must be carefully controlled to avoid adverse effects on disintegration and dissolution . Research by Shangraw (1989) highlighted that while starch benefits from improved flow, the hydrophobic nature of some glidants can hinder its disintegrant properties, necessitating a balanced approach .

Mechanistic Insights

The mechanistic action of glidants involves a combination of physical and chemical interactions with the powder particles. Colloidal silicon dioxide, for example, acts through a mechanical interlocking mechanism, where its fine particles fill the voids between larger excipient particles, thereby reducing friction and improving flow . Magnesium stearate, on the other hand, provides a lubricating layer on the surface of the particles, reducing cohesive forces but potentially creating a hydrophobic barrier that can affect dissolution .

Practical Considerations

In practice, the selection of glidants must consider the overall formulation strategy, including the type of API, the desired release profile, and the manufacturing process. The optimal concentration of glidants is typically determined through empirical testing, where flow properties, compressibility, hardness, disintegration, and dissolution are systematically evaluated. Furthermore, the interaction between glidants and other excipients, as well as the API, must be studied to ensure compatibility and stability.

Conclusion

The addition of glidants to pharmaceutical excipients plays a critical role in optimizing the tabletting process. While glidants enhance the flow properties of powder blends, their concentration and type must be carefully selected to balance flowability with tablet hardness, disintegration, and dissolution properties. Further research and controlled experimentation are essential to tailor the use of glidants for specific formulations, ensuring the quality and efficacy of the final pharmaceutical product.

References

1. Aulton, M.E., & Taylor, K.M.G. (2017). Aulton's Pharmaceutics: The Design and Manufacture of Medicines. Elsevier.
2. Rowe, R.C., Sheskey, P.J., & Quinn, M.E. (2009). Handbook of Pharmaceutical Excipients. Pharmaceutical Press.
3. Osei-Yeboah, F., & Sun, C.C. (2015). "Validation and applications of an expedited tablet friability method." Journal of Pharmaceutical Sciences, 104(4), 1459-1466.
4. Hlinak, A.J., et al. (2006). "Understanding the impact of microcrystalline cellulose properties on the particle size and shape of extruded-spheronized pellets." International Journal of Pharmaceutics, 307(1), 69-76.
5. Vranikova, B., et al. (2013). "Effect of lubricants on the compaction and compression of directly compressible materials." Drug Development and Industrial Pharmacy, 39(8), 1263-1271.
6. Sun, C.C. (2011). "Setting the bar for powder flow properties in successful solid dosage form development." Pharmaceutical Research, 28(7), 1622-1630.
7. Patel, S., et al. (2007). "The effect of excipients on the disintegration and dissolution of aspirin tablets." International Journal of Pharmaceutics, 331(2), 32-37.
8. Jivraj, M., et al. (2000). "An overview of the different excipients useful for the direct compression of tablets." Pharmaceutical Science & Technology Today, 3(2), 58-63.
9. Gohel, M.C., & Jogani, P.D. (2005). "A review of co-processed directly compressible excipients." Journal of Pharmacy & Pharmaceutical Sciences, 8(1), 76-93.
10. Shangraw, R.F. (1989). "Direct compression tableting." Pharmaceutical Dosage Forms: Tablets, Vol. 1. Marcel Dekker, Inc.
11. Bolhuis, G.K., & Armstrong, N.A. (2006). "Excipients for direct compaction – an update." Pharmaceutical Development and Technology, 11(1), 111-124.
12. Alderborn, G. (2013). "Tabletting." In Pharmaceutics: The Science of Dosage Form Design (2nd ed.), edited by Aulton, M.E., Elsevier.
13. Hauschild, K., & Picker-Freyer, K.M. (2006). "Evaluation of a new coprocessed compound based on lactose and maize starch for tablet formulation." AAPS PharmSciTech, 7(3), E72-E79.
14. Liu, L.X., & Marroum, P.J. (2010). "Development and regulation of generic modified-release products in the US." Drug Discovery Today, 15(15-16), 725-731.
15. Yalkowsky, S.H., & Bolton, S. (1990). "Effect of lubricants on content uniformity of a low dose drug." Journal of Pharmaceutical Sciences, 79(9), 784-786.
16. Shangraw, R.F., & Demarest, D.A. (1993). "A survey of current industrial practices in the formulation and manufacture of tablets and capsules." Pharmaceutical Technology, 17(1), 32-44.